Pharmabiz
 

Sealantis' vascular sealing, V-Seal receives CE Mark approval

Haifa, IsraelMonday, August 5, 2013, 17:00 Hrs  [IST]

Sealantis, a start-up that develops private algo-mimetic tissue adhesives, has received CE Mark approval for its product vascular sealing, Seal-V. It is a bioresorbable sealant without proteins designed to produce hemostasis by mechanically sealing areas of leakage risk for surgical reconstruction of large blood vessels such as the carotid artery, femoral artery, brachial or iliac.

Seal-V is the next generation of tissue sealant. Its algo-mimetic gives the intrinsic ability to bind strongly to the native as synthetic grafts blood vessels, even in wet conditions. In addition, the composition without protein-Seal V exempts the risks associated with the use of protein-based products. Unlike the hemostats designed to cause coagulation of the blood, the effectiveness of V-Seal does not depend on the presence of blood and this can be used as a prophylactic sealing.

"We are very pleased to market V-Seal in the European market and to give surgeons a new and better option for the control of bleeding on the suture lines," said Tomer Fuchs, CEO of Sealantis. Fuchs has recently joined the company after serving during more than twenty years of senior positions in global companies such as Medtronic Ventor, ANORAD and Vishay.

"Sealantis worked closely with surgeons to take advantage of the algo-mimetic technology and design products that occupy a strong position in the market for wound closure, estimated at several billion dollars," adds Dr Zeev Gilkis, president, Sealantis.

In addition to V-Seal, Sealantis also has in its pipeline of advanced solutions for different clinical needs. Among them there are such a product of gastrointestinal seal designed to prevent leakage of intestinal contents from anastomoses, a potentially fatal complication of abdominal surgery, an adhesive for the obliteration of space for plastic surgery which can significantly reduce healing time for facial and body facelifts, and innovative combinations thereof for the release of specific drugs to a site.

Sealantis currently working on strategic partnerships for the upcoming launch of V-Seal on the market.

 
[Close]